（文章来源：每日经济新闻） 中信建投指出，医疗器械板块的长期投资机会来自创新、出海和并购整合，板块的创新性和国际化能力 得到认可，估值正在重构。短期来看，Q4和26年业绩改善个股存在业绩估值修复机会，部分公司25年 比24年加速增长，26年有望迎来业绩拐点。医疗设备板块25年Q3收入和净利润同比高增长，招投标持 续修复；高值耗材板块缓慢复苏，电生理等赛道集采逐步出清；IVD板块受集采和检验套餐解绑影响承 压，但部分公司海外业务高增长。建议关注市场空间大、国产化率低的创新器械赛道，如PFA、RDN、 TAVR等产品，以及脑机接口、AI医疗、手术机器人等新科技方向。长期看好中国医疗器械企业通过改 进式创新和国际化成长为全球龙头。 医疗ETF（159828）跟踪的是中证医疗指数（399989），该指数从沪深市场中选取涉及医疗器械、医疗 服务和医疗信息化等领域的上市公司证券作为指数样本，以反映医疗主题相关上市公司证券的整体表 现。中证医疗指数以医药生物行业为主，侧重于中小市值公司，具有较为明显的周期性波动特征。 ...

Core Insights - The company reported revenue and net profit of 1.867 billion and 623 million yuan for the first three quarters of 2025, representing year-over-year growth of 22.5% and 18.0% respectively, with Q3 alone showing revenue and net profit of 654 million and 198 million yuan, reflecting growth of 24.8% and 6.8% year-over-year [1] - The company is expected to maintain a positive development trend in 2025 due to its leading product performance and strengthening commercialization capabilities both domestically and internationally [1] Financial Performance - The gross margin for the first three quarters of 2025 was 73.2%, an increase of 0.5 percentage points year-over-year, driven by a higher proportion of revenue from high-end new products [1] - The company’s operating cash flow for the first three quarters of 2025 was 676 million yuan, showing a year-over-year increase of 29.1%, indicating continuous improvement in cash flow levels [1] Business Segments - The electrophysiology segment is expected to see rapid growth, with PFA procedures exceeding 2,000 by August 2025, and an anticipated total of 4,500 procedures for the year [2] - The vascular intervention segment is also projected to grow quickly, supported by the increasing market recognition of products like coronary guiding catheters and peripheral intervention products [3] - The non-vascular intervention segment is expected to contribute to revenue growth due to the continuous improvement of the product matrix and clinical recognition [3] Profit Forecast and Valuation - The net profit forecast for 2025-2027 has been adjusted to 824 million, 1.072 billion, and 1.393 billion yuan, reflecting a downward adjustment of 9% to 10% [4] - The company is positioned as a leading player in the domestic electrophysiology and vascular intervention markets, with a target price of 387.58 yuan for 2026, based on a 51x PE ratio [4]

Core Viewpoint - Yonghe Co., Ltd. (SH605020) expects a significant increase in net profit for the first three quarters of 2025, projecting a year-on-year growth of 211.59% to 225.25% [1][2] Financial Performance - The company anticipates a net profit attributable to shareholders of 456 million to 476 million yuan for the first three quarters of 2025, an increase of 310 million to 330 million yuan compared to the same period last year [2] - For Q3 2025, the expected net profit is between 185 million to 205 million yuan, reflecting a year-on-year growth of 447.64% to 506.85% and a quarter-on-quarter increase of 6.34% to 17.83% [2] - The net profit excluding non-recurring gains and losses for the first three quarters of 2025 is projected to be between 442 million to 462 million yuan, a year-on-year increase of 212.93% to 227.10% [2] - The Q3 2025 net profit excluding non-recurring items is expected to be between 174 million to 194 million yuan, with a year-on-year growth of 396.82% to 453.92% and a quarter-on-quarter increase of 1.71% to 13.40% [2] Industry Context - The performance increase is attributed to the sustained high demand in the refrigerant industry, driven by supply-side quota policies and steady growth in downstream demand [3] - The reduction in production quotas for second-generation refrigerants (HCFCs) and the implementation of quota management for third-generation refrigerants (HFCs) have optimized the supply-demand structure [3] - The steady growth in demand from sectors such as air conditioning and cold chain logistics supports rising product prices and improved profit margins [3] Operational Efficiency - The company has optimized production efficiency at its Shaowu Yonghe base, enhancing the quality and sales scale of products like HFP, FEP, PTFE, and PFA [3] - The transition from "capacity construction" to "efficiency release" is expected to lead to continuous profitability starting from Q4 2024 [3] - The company aims to broaden its profit margins and improve operational efficiency through lean management, market share expansion, and cost control [3] Company Background - Yonghe Co., Ltd. specializes in the research, production, and sales of fluorochemical products, with a comprehensive industrial chain covering fluorite resources, hydrofluoric acid, fluorocarbon chemicals, and fluorinated polymers [7] - The company reported a revenue of 2.445 billion yuan for the first half of 2025, marking a year-on-year increase of 12.39% [7] - The net profit attributable to shareholders for the same period was 271 million yuan, reflecting a year-on-year growth of 140.82% [7]

Core Viewpoint - Yonghe Co., Ltd. (605020.SH) is experiencing significant growth in its performance, with a projected net profit increase of 211.59% to 225.25% year-on-year for the first three quarters of 2025, driven by the high demand in the refrigerant industry [1][2] Financial Performance - The company expects a net profit of 4.56 billion to 4.76 billion yuan for the first three quarters of 2025, with the third quarter alone projected to yield a net profit of 1.85 billion to 2.05 billion yuan, marking a year-on-year increase of 447.64% to 506.85% [2][3] - In Q4 2024, Yonghe's revenue was 12.27 billion yuan, up 7.64% year-on-year, with a net profit of 1.05 billion yuan, reflecting a 384.97% increase [3] Industry Dynamics - The growth is attributed to the sustained high demand in the refrigerant industry, with production quotas for second-generation hydrofluorocarbons (HCFCs) being reduced and third-generation hydrofluorocarbons (HFCs) continuing to face quota management, leading to an optimized supply-demand structure [2][4] - The company has secured a total HFCs product quota of 58,200 tons, positioning it among the top in the industry to benefit from supply-side reforms [4][5] Product and Operational Efficiency - Yonghe has optimized its production lines, enhancing the quality and scale of products such as HFP, FEP, PTFE, and PFA, transitioning from capacity construction to efficiency release [2][4] - The fluorocarbon chemical business, which is the company's primary revenue driver, achieved 13.1 billion yuan in revenue in the first half of 2025, accounting for 53.58% of total revenue, with a gross margin increase to 32.43% [4][5] Cash Flow and Profitability - The company's cash flow from operating activities for the first half of 2025 reached 3.37 billion yuan, a year-on-year increase of 209.39%, indicating improved financial health [3]

Core Viewpoint - Yonghe Co., Ltd. expects a significant increase in net profit attributable to shareholders for the first three quarters of 2025, driven by the sustained high demand in the refrigerant industry [1][3]. Financial Performance - The company anticipates a net profit of between 456 million to 476 million CNY for the first three quarters, representing a year-on-year growth of 211.59% to 225.25% [1]. - For the third quarter alone, Yonghe expects a net profit of 185 million to 205 million CNY, indicating a year-on-year increase of 447.64% to 506.85% and a quarter-on-quarter growth of 6.34% to 17.83% [3]. Industry Context - The refrigerant industry continues to experience high demand due to supply-side quota policies and steady growth in downstream demand, particularly in air conditioning and cold chain sectors [6][8]. - The transition from second-generation refrigerants (HCFCs) to third-generation refrigerants (HFCs) is ongoing, with production quotas tightening, which enhances the supply-demand structure [6][8]. Operational Strategy - Yonghe Co., Ltd. is optimizing its product structure and enhancing operational efficiency across its production bases, which is expected to lead to sustained profitability starting from Q4 2024 [6]. - The company is leveraging its complete industrial chain from fluorite mining to fine chemical products to capture market opportunities and improve profitability through lean management and market expansion [6][8]. Market Outlook - The overall outlook for the refrigerant market remains optimistic, with expectations of continued demand growth driven by consumer upgrades and technological innovations [11]. - The domestic refrigerant market is primarily driven by air conditioning (62.18%), refrigerators (4.78%), and automotive applications (9.87%) [8].

Core Viewpoint - Yonghe Co., Ltd. (605020.SH) expects a net profit attributable to shareholders of 456 million to 476 million yuan for the first three quarters of 2025, representing a year-on-year increase of 211.59% to 225.25% due to the sustained high prosperity of the refrigerant industry [1] Industry Summary - The refrigerant industry continues to maintain a high prosperity level, benefiting from supply-side quota policies and steady growth in downstream demand. The production quotas for second-generation fluorinated refrigerants (HCFCs) are continuously reduced, and third-generation fluorinated refrigerants (HFCs) are still subject to production quota management, which strengthens supply-side constraints and optimizes the supply-demand structure [1][1] - Steady growth in demand from downstream sectors such as air conditioning and cold chain supports continuous price increases and steady improvement in gross margins [1] Company Summary - The company is optimizing production line efficiency at its Shaowu Yonghe production base, enhancing the yield and sales scale of products such as HFP, FEP, PTFE, and PFA, transitioning from "capacity construction" to "efficiency release" [1] - From the fourth quarter of 2024, Shaowu Yonghe is expected to achieve sustained profitability [1] - The company leverages its full industry chain layout from upstream fluorite resources to downstream fluorinated fine chemicals, seizing market opportunities through lean internal management, expanding market share, and strengthening cost control to further widen profit margins and enhance operational efficiency [1]

Group 1 - The core viewpoint is that by 2025, domestic PFA brands are expected to enter a rapid commercialization phase, gradually replacing traditional radiofrequency and cryoablation technologies due to their non-thermal ablation characteristics, shorter operation times, lower complication risks, and better long-term efficacy [1] - Six domestic brands have already been approved, indicating a growing market presence [1] - The National Medical Products Administration has approved measures to optimize the lifecycle regulation to support the innovation and development of high-end medical devices, which includes ten initiatives aimed at promoting the development of medical robots, high-end medical imaging equipment, AI medical devices, and new biological materials [1] Group 2 - The medical device sector is currently valued at historical lows, with policy benefits expected to materialize starting from Q2 2025, particularly in the AI + imaging/surgery direction [1] - The innovative drug sector is experiencing short-term fluctuations but is viewed positively in the long term, driven by accelerated overseas expansion and changes in payment systems [1] - The traditional Chinese medicine sector is seeing reduced impacts from centralized procurement, with improved gross margins for OTC products; the blood products industry is experiencing increased concentration and favorable demand for immunoglobulin [1] Group 3 - The retail pharmacy industry is undergoing accelerated clearing, with AI empowerment enhancing operational efficiency and outpatient coordination creating incremental opportunities [1] - The CXO sector is gradually stabilizing in performance, with a recovery in overseas investment and financing driving industry growth [1] Group 4 - The ChiNext Medical ETF tracks the ChiNext Medical Index, which is compiled by China Securities Index Co., Ltd., selecting listed companies in the medical and health industry from the ChiNext market to reflect the overall performance of the medical and biological sector [2] - This index focuses on high-growth and innovative sub-sectors such as biomedicine, medical devices, and medical services, effectively showcasing the investment value and development potential of the ChiNext medical industry [2]

Financial Data and Key Metrics Changes - The company reported a revenue growth of 55.4% in the last quarter, with an operating margin of 27.8% and an EPS growth of 11% [21][22][27] - The company ended the fiscal year with a billion dollars in the cardiac ablation business, aiming to double that in the near term [8][26] Business Line Data and Key Metrics Changes - The cardiac ablation solutions (CAS) business reached a billion dollars in revenue, with expectations to reach a $2 billion run rate soon [85][86] - The diabetes business has shown six consecutive quarters of double-digit growth, indicating a strong pipeline and readiness for separation [25][42] Market Data and Key Metrics Changes - The total addressable market (TAM) for hypertension therapy is significant, with 18 million patients in the U.S. potentially benefiting from the therapy, translating to $2 to $3 billion in revenue for every 1% market penetration [10][102] - The cardiac ablation market is valued at $10 billion and is growing at over 20% [7][85] Company Strategy and Development Direction - The company is focusing on innovation-driven growth across three main portfolios: cardiovascular, neuroscience, and surgery, with a strong emphasis on technology differentiation [4][5][56] - The decision to separate the diabetes business is aimed at allowing the company to focus more on higher profit areas, which are expected to accelerate growth [25][44] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the health of end markets driven by demographics and innovation, stating that it is a good time to be in med tech [12][13] - The company is committed to increasing R&D investment and capital allocation towards higher growth markets, with a focus on synergies across product lines [23][30] Other Important Information - The company is increasing R&D investment faster than revenue for the first time in four years, indicating a strategic shift towards innovation [23][24] - Management highlighted the importance of AI, robotics, and sensing technologies in enhancing product offerings and operational efficiency [14][18] Q&A Session Summary Question: Why is now the right time to separate the diabetes business? - Management indicated that the diabetes business is now healthy and ready to stand alone, allowing Medtronic to focus on faster growth in other areas [44][45] Question: What are the expected benefits of the diabetes separation? - The separation is expected to unlock shareholder value and allow for more focused investment in higher profit areas [26][49] Question: How does the company plan to improve gross margins? - Management discussed strategies including better pricing governance, cost reductions, and addressing mix headwinds from diabetes and CAS [63][67] Question: What is the outlook for EPS growth in fiscal 2027? - Management expects high single-digit EPS growth in fiscal 2027 following the diabetes separation [80][81]